Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veris Residential

15.80
-0.2800-1.74%
Pre-market: 15.72-0.0800-0.51%07:17 EDT
Volume:723.92K
Turnover:11.44M
Market Cap:1.47B
PE:-41.98
High:16.15
Open:15.30
Low:15.30
Close:16.08
Loading ...

Veris Residential Q4 Adjusted Ffo per Share USD 0.11

THOMSON REUTERS
·
25 Feb

Veris Residential Inc FY2025 Ffo Shr View $0.60 -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Press Release: Veris Residential, Inc. Reports Fourth Quarter and Full Year 2024 Results

Dow Jones
·
25 Feb

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

CNW Group
·
24 Feb

Veris Residential Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
22 Feb

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

PR Newswire
·
19 Feb

Veris Residential Announces Tax Treatment of 2024 Distributions

THOMSON REUTERS
·
18 Feb

Press Release: Veris Residential Announces Tax Treatment of 2024 Distributions

Dow Jones
·
18 Feb

Is it Prudent to Retain Mid-America Stock in Your Portfolio Now?

Zacks
·
14 Feb

Should Essex Property Stock Be Retained in Your Portfolio Now?

Zacks
·
07 Feb

Should You Retain Camden Property Stock in Your Portfolio Now?

Zacks
·
31 Jan

Veris Residential, Inc. Announces Dates for Fourth Quarter and Full Year 2024 Financial Results and Webcast

PR Newswire
·
23 Jan

Here's Why You Should Retain AvalonBay in Your Portfolio Now

Zacks
·
17 Jan

3 Residential REITs to Buy Despite Ongoing Industry Challenges

Zacks
·
16 Jan

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

GlobeNewswire
·
15 Jan

Here's Why it is Wise to Retain UDR Stock in Your Portfolio Now

Zacks
·
14 Jan

UDR Announces Preliminary Q4 Results & Investment Activity Update

Zacks
·
07 Jan

Should Essex Property Stock Be Retained in Your Portfolio Now?

Zacks
·
07 Jan

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire
·
07 Jan

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

PR Newswire
·
06 Jan